Think Investments’s Inovio Pharmaceuticals INO Stock Holding History

Think Investments’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-26,667	Closed	-$2.83M	–	30
2020 Q4	$2.83M	Buy	+26,667	New	+$3.55M	0.43%	23

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Think Investments's INO Position: Q1 2021 in Review

Think Investments sold out of Inovio Pharmaceuticals (INO) in Q1 2021, closing a stake of 26,667 shares — an estimated $2.83M sold.

Think Investments first reported a position in INO in Q4 2020 and held it in 1 quarter. The position peaked at $2.83M in Q4 2020. 218 funds tracked by Wall St. Rank hold INO as of Q1 2021.

Think Investments reported no remaining Inovio Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Think Investments sold 26,667 Inovio Pharmaceuticals shares in Q1 2021, an estimated $2.83M.
Think Investments first reported a position in Inovio Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Think Investments's Inovio Pharmaceuticals position peaked at $2.83M in Q4 2020.
218 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2021.

Based on Think Investments's 13F filing for Q1 2021, filed 17 May 2021.